Olivier Godeaux, MD, MPH

Dynavax Technologies Corporation

Disclosure(s): Dynavax: Advisor/Consultant

Poster(s):

• 121 - Safety, Tolerability, and Pertussis Immunogenicity Findings From a Randomized, Participant-Blinded, Active-Controlled, Dose-Escalating, Phase 1 Trial of a Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018 CpG Adjuvanted) Compared With Boostrix in Healthy Adults Aged 18 to 22 Years
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET